Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Neoplasms | 40 | 2024 | 22170 | 1.860 |
Why?
|
Immunotherapy | 25 | 2024 | 4652 | 1.640 |
Why?
|
Medical Oncology | 10 | 2024 | 2321 | 1.070 |
Why?
|
Melanoma | 14 | 2024 | 5709 | 0.900 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 29 | 2024 | 11742 | 0.890 |
Why?
|
Clinical Trials as Topic | 13 | 2024 | 8002 | 0.850 |
Why?
|
Mesothelioma | 6 | 2024 | 807 | 0.720 |
Why?
|
Biliary Tract Neoplasms | 3 | 2022 | 185 | 0.700 |
Why?
|
GPI-Linked Proteins | 6 | 2024 | 469 | 0.640 |
Why?
|
Drug Discovery | 3 | 2017 | 1051 | 0.600 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 8 | 2024 | 5315 | 0.590 |
Why?
|
Antibodies, Monoclonal | 12 | 2024 | 9177 | 0.550 |
Why?
|
Antibodies, Bispecific | 4 | 2024 | 196 | 0.540 |
Why?
|
Biological Therapy | 1 | 2018 | 141 | 0.540 |
Why?
|
National Cancer Institute (U.S.) | 4 | 2023 | 297 | 0.540 |
Why?
|
Interleukin-18 | 1 | 2018 | 250 | 0.530 |
Why?
|
Eye Diseases | 1 | 2021 | 653 | 0.510 |
Why?
|
Hepatitis, Autoimmune | 1 | 2018 | 172 | 0.500 |
Why?
|
Skin Neoplasms | 8 | 2024 | 5821 | 0.500 |
Why?
|
Drugs, Investigational | 1 | 2017 | 212 | 0.490 |
Why?
|
Myocarditis | 1 | 2022 | 788 | 0.470 |
Why?
|
Carcinoma, Merkel Cell | 4 | 2021 | 328 | 0.470 |
Why?
|
Lung Neoplasms | 11 | 2024 | 13380 | 0.460 |
Why?
|
Autoimmunity | 2 | 2019 | 1356 | 0.460 |
Why?
|
Pleural Neoplasms | 3 | 2024 | 609 | 0.420 |
Why?
|
Petunia | 2 | 2023 | 3 | 0.420 |
Why?
|
Carcinoma, Hepatocellular | 3 | 2023 | 2298 | 0.420 |
Why?
|
Research Design | 3 | 2023 | 6180 | 0.400 |
Why?
|
Rare Diseases | 3 | 2024 | 622 | 0.400 |
Why?
|
Disease Susceptibility | 1 | 2018 | 1787 | 0.390 |
Why?
|
Antineoplastic Agents | 9 | 2024 | 13639 | 0.380 |
Why?
|
Developing Countries | 1 | 2024 | 2885 | 0.380 |
Why?
|
Humans | 110 | 2024 | 761504 | 0.380 |
Why?
|
Asbestos | 1 | 2013 | 251 | 0.370 |
Why?
|
Iodine Radioisotopes | 1 | 2014 | 1031 | 0.370 |
Why?
|
Receptor, IGF Type 1 | 1 | 2013 | 379 | 0.360 |
Why?
|
Adenoma, Pleomorphic | 1 | 2010 | 75 | 0.330 |
Why?
|
Liver Neoplasms | 3 | 2023 | 4320 | 0.330 |
Why?
|
Carcinoma, Papillary | 1 | 2014 | 785 | 0.330 |
Why?
|
Hodgkin Disease | 3 | 2023 | 1378 | 0.320 |
Why?
|
Thyroidectomy | 1 | 2014 | 907 | 0.320 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2023 | 1551 | 0.310 |
Why?
|
Patient Selection | 1 | 2020 | 4244 | 0.310 |
Why?
|
Extracellular Matrix Proteins | 1 | 2013 | 829 | 0.310 |
Why?
|
Adverse Drug Reaction Reporting Systems | 3 | 2024 | 494 | 0.300 |
Why?
|
Molecular Targeted Therapy | 4 | 2021 | 2811 | 0.290 |
Why?
|
Combined Modality Therapy | 8 | 2022 | 8529 | 0.270 |
Why?
|
Anilides | 3 | 2024 | 411 | 0.270 |
Why?
|
Salivary Gland Neoplasms | 1 | 2010 | 304 | 0.270 |
Why?
|
Lupus Erythematosus, Systemic | 1 | 2018 | 2155 | 0.260 |
Why?
|
Tuberculosis | 1 | 2019 | 2017 | 0.260 |
Why?
|
Neoplasm Staging | 10 | 2024 | 11121 | 0.260 |
Why?
|
Pandemics | 3 | 2024 | 8654 | 0.250 |
Why?
|
Flowers | 2 | 2023 | 31 | 0.240 |
Why?
|
HIV Infections | 5 | 2023 | 17351 | 0.240 |
Why?
|
Trinidad and Tobago | 1 | 2024 | 13 | 0.240 |
Why?
|
Neuroendocrine Tumors | 2 | 2021 | 641 | 0.230 |
Why?
|
Adrenocortical Carcinoma | 1 | 2024 | 88 | 0.220 |
Why?
|
Sarcoma, Alveolar Soft Part | 1 | 2023 | 43 | 0.220 |
Why?
|
Aged | 38 | 2024 | 169289 | 0.220 |
Why?
|
Fibromatosis, Aggressive | 1 | 2024 | 126 | 0.220 |
Why?
|
Middle Aged | 42 | 2024 | 220895 | 0.220 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 2 | 2024 | 664 | 0.220 |
Why?
|
Th1 Cells | 2 | 2019 | 1036 | 0.210 |
Why?
|
Genomics | 4 | 2024 | 5821 | 0.210 |
Why?
|
Urogenital Neoplasms | 1 | 2024 | 131 | 0.210 |
Why?
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2024 | 226 | 0.210 |
Why?
|
Antibodies, Blocking | 1 | 2023 | 243 | 0.200 |
Why?
|
Paraneoplastic Syndromes | 1 | 2024 | 155 | 0.200 |
Why?
|
Plant Proteins | 2 | 2023 | 370 | 0.200 |
Why?
|
Occupational Exposure | 1 | 2013 | 1813 | 0.200 |
Why?
|
Gallbladder Neoplasms | 1 | 2024 | 189 | 0.200 |
Why?
|
Kidney Neoplasms | 3 | 2024 | 4249 | 0.200 |
Why?
|
Radiation Dosage | 2 | 2020 | 1958 | 0.200 |
Why?
|
Aged, 80 and over | 22 | 2024 | 58976 | 0.190 |
Why?
|
Bees | 1 | 2021 | 46 | 0.190 |
Why?
|
SEER Program | 2 | 2024 | 1450 | 0.190 |
Why?
|
Thyroid Neoplasms | 1 | 2014 | 2332 | 0.190 |
Why?
|
Carcinoma, Renal Cell | 3 | 2023 | 3164 | 0.180 |
Why?
|
Leukemia, B-Cell | 1 | 2021 | 84 | 0.180 |
Why?
|
Monitoring, Immunologic | 1 | 2021 | 98 | 0.180 |
Why?
|
Female | 48 | 2024 | 392644 | 0.180 |
Why?
|
Male | 44 | 2024 | 360804 | 0.180 |
Why?
|
Consensus | 4 | 2023 | 3123 | 0.170 |
Why?
|
Truth Disclosure | 1 | 2024 | 434 | 0.170 |
Why?
|
Arabidopsis | 1 | 2023 | 465 | 0.170 |
Why?
|
Adult | 32 | 2024 | 221177 | 0.160 |
Why?
|
Cancer Vaccines | 2 | 2020 | 1051 | 0.160 |
Why?
|
Neoplasm, Residual | 1 | 2024 | 1008 | 0.160 |
Why?
|
Recombinant Fusion Proteins | 3 | 2024 | 3734 | 0.160 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2023 | 12148 | 0.160 |
Why?
|
Hemangiosarcoma | 1 | 2021 | 215 | 0.160 |
Why?
|
Sezary Syndrome | 1 | 2019 | 80 | 0.160 |
Why?
|
Maryland | 1 | 2019 | 277 | 0.160 |
Why?
|
Pyrimidinones | 1 | 2021 | 385 | 0.150 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2023 | 686 | 0.150 |
Why?
|
Retrospective Studies | 12 | 2024 | 80636 | 0.150 |
Why?
|
Joints | 1 | 2020 | 322 | 0.150 |
Why?
|
Protein Kinase Inhibitors | 2 | 2021 | 5671 | 0.150 |
Why?
|
Receptor, erbB-2 | 2 | 2024 | 2557 | 0.150 |
Why?
|
Multiple Organ Failure | 1 | 2020 | 387 | 0.150 |
Why?
|
Mycosis Fungoides | 1 | 2019 | 170 | 0.150 |
Why?
|
Lymphoma, AIDS-Related | 1 | 2018 | 79 | 0.150 |
Why?
|
Kupffer Cells | 1 | 2018 | 143 | 0.140 |
Why?
|
Antibodies, Neutralizing | 3 | 2024 | 1943 | 0.140 |
Why?
|
Pyridines | 3 | 2024 | 2875 | 0.140 |
Why?
|
Neoplastic Syndromes, Hereditary | 1 | 2019 | 245 | 0.140 |
Why?
|
United States | 11 | 2024 | 72334 | 0.140 |
Why?
|
Bile Duct Neoplasms | 1 | 2022 | 605 | 0.140 |
Why?
|
Virus Internalization | 1 | 2020 | 497 | 0.140 |
Why?
|
Granuloma | 1 | 2019 | 328 | 0.140 |
Why?
|
Receptors, Aryl Hydrocarbon | 1 | 2018 | 220 | 0.130 |
Why?
|
Immunity | 2 | 2020 | 996 | 0.130 |
Why?
|
Nasopharyngeal Neoplasms | 1 | 2019 | 290 | 0.130 |
Why?
|
Neoplasms, Experimental | 1 | 2021 | 1229 | 0.130 |
Why?
|
Guanine | 2 | 2014 | 279 | 0.130 |
Why?
|
Glutamates | 2 | 2014 | 389 | 0.130 |
Why?
|
Vascular Endothelial Growth Factor A | 3 | 2024 | 3492 | 0.130 |
Why?
|
Oximes | 1 | 2017 | 303 | 0.130 |
Why?
|
Small Cell Lung Carcinoma | 1 | 2020 | 423 | 0.120 |
Why?
|
Carcinoma, Transitional Cell | 1 | 2022 | 782 | 0.120 |
Why?
|
Matrix Metalloproteinases | 1 | 2018 | 393 | 0.120 |
Why?
|
Natural Language Processing | 1 | 2024 | 1162 | 0.120 |
Why?
|
Lymphoma, B-Cell | 1 | 2022 | 940 | 0.120 |
Why?
|
Immunoconjugates | 2 | 2024 | 954 | 0.120 |
Why?
|
Diarrhea | 1 | 2021 | 1318 | 0.120 |
Why?
|
Hematopoietic Stem Cell Transplantation | 2 | 2024 | 5671 | 0.120 |
Why?
|
Salvage Therapy | 1 | 2021 | 1264 | 0.120 |
Why?
|
Recurrence | 6 | 2024 | 8465 | 0.120 |
Why?
|
Disease-Free Survival | 5 | 2024 | 6814 | 0.120 |
Why?
|
Pancreatic Neoplasms | 1 | 2012 | 5368 | 0.120 |
Why?
|
Drug Evaluation, Preclinical | 2 | 2017 | 1334 | 0.110 |
Why?
|
Fatal Outcome | 1 | 2019 | 1834 | 0.110 |
Why?
|
Congresses as Topic | 1 | 2019 | 803 | 0.110 |
Why?
|
Myelodysplastic Syndromes | 1 | 2023 | 1394 | 0.110 |
Why?
|
Animals | 12 | 2024 | 168459 | 0.110 |
Why?
|
Immunomodulation | 1 | 2017 | 549 | 0.110 |
Why?
|
Medical Records | 1 | 2018 | 1408 | 0.110 |
Why?
|
Antibodies, Viral | 1 | 2024 | 3156 | 0.110 |
Why?
|
Colitis | 1 | 2021 | 1233 | 0.110 |
Why?
|
Herpesvirus 4, Human | 1 | 2018 | 1078 | 0.110 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2014 | 326 | 0.100 |
Why?
|
Virus Replication | 1 | 2020 | 2435 | 0.100 |
Why?
|
Pharmaceutical Preparations | 1 | 2020 | 1089 | 0.100 |
Why?
|
T-Lymphocytes, Helper-Inducer | 1 | 2018 | 974 | 0.100 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2018 | 612 | 0.100 |
Why?
|
Oncolytic Virotherapy | 1 | 2018 | 516 | 0.100 |
Why?
|
Program Evaluation | 1 | 2020 | 2495 | 0.100 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2023 | 1640 | 0.100 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2021 | 2425 | 0.100 |
Why?
|
Pentostatin | 1 | 2011 | 26 | 0.100 |
Why?
|
Neoadjuvant Therapy | 1 | 2023 | 2827 | 0.100 |
Why?
|
Insulin-Like Growth Factor II | 1 | 2013 | 269 | 0.100 |
Why?
|
Immunotoxins | 1 | 2012 | 175 | 0.100 |
Why?
|
Prospective Studies | 10 | 2024 | 54425 | 0.100 |
Why?
|
Leukocytes, Mononuclear | 3 | 2024 | 1844 | 0.090 |
Why?
|
Treatment Outcome | 12 | 2024 | 64680 | 0.090 |
Why?
|
Imidazoles | 1 | 2017 | 1180 | 0.090 |
Why?
|
Societies, Medical | 1 | 2023 | 3905 | 0.090 |
Why?
|
Pregnancy Outcome | 1 | 2021 | 2921 | 0.090 |
Why?
|
Pyrazoles | 1 | 2021 | 2009 | 0.090 |
Why?
|
Perception | 1 | 2017 | 1197 | 0.090 |
Why?
|
Enzyme Inhibitors | 1 | 2021 | 3712 | 0.090 |
Why?
|
Dendritic Cells | 2 | 2020 | 2747 | 0.090 |
Why?
|
Colorectal Neoplasms | 2 | 2021 | 6935 | 0.090 |
Why?
|
Sarcoma | 1 | 2021 | 1801 | 0.090 |
Why?
|
Phylogeny | 3 | 2024 | 2811 | 0.090 |
Why?
|
Neoplasm Metastasis | 4 | 2022 | 4915 | 0.090 |
Why?
|
Radiotherapy Dosage | 3 | 2022 | 2898 | 0.090 |
Why?
|
T-Lymphocyte Subsets | 1 | 2018 | 1802 | 0.080 |
Why?
|
Remission Induction | 3 | 2024 | 2396 | 0.080 |
Why?
|
Evidence-Based Medicine | 1 | 2021 | 3688 | 0.080 |
Why?
|
Cell Cycle Proteins | 1 | 2021 | 3448 | 0.080 |
Why?
|
Artificial Intelligence | 1 | 2024 | 2578 | 0.080 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2022 | 2223 | 0.080 |
Why?
|
Signal Transduction | 3 | 2018 | 23445 | 0.080 |
Why?
|
Kaplan-Meier Estimate | 4 | 2024 | 6484 | 0.080 |
Why?
|
Deoxycytidine | 2 | 2011 | 877 | 0.080 |
Why?
|
Electronic Health Records | 2 | 2024 | 4811 | 0.080 |
Why?
|
Communication | 1 | 2023 | 3873 | 0.080 |
Why?
|
Head and Neck Neoplasms | 1 | 2023 | 2895 | 0.080 |
Why?
|
Indoles | 1 | 2017 | 1833 | 0.080 |
Why?
|
Immune Tolerance | 1 | 2018 | 2303 | 0.080 |
Why?
|
Prednisone | 2 | 2024 | 1563 | 0.080 |
Why?
|
Kidney Transplantation | 1 | 2024 | 4234 | 0.080 |
Why?
|
Killer Cells, Natural | 1 | 2018 | 2200 | 0.080 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2020 | 2020 | 0.080 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2023 | 3613 | 0.070 |
Why?
|
Mycobacterium tuberculosis | 1 | 2019 | 1914 | 0.070 |
Why?
|
Liver | 1 | 2023 | 7529 | 0.070 |
Why?
|
Sulfonamides | 1 | 2017 | 1978 | 0.070 |
Why?
|
Peritoneal Neoplasms | 1 | 2013 | 711 | 0.070 |
Why?
|
Drug Combinations | 1 | 2013 | 2048 | 0.070 |
Why?
|
Adjuvants, Immunologic | 2 | 2023 | 1036 | 0.070 |
Why?
|
Autoimmune Diseases | 1 | 2019 | 2244 | 0.070 |
Why?
|
Drug Administration Schedule | 3 | 2021 | 4853 | 0.070 |
Why?
|
B-Lymphocytes | 2 | 2018 | 4758 | 0.070 |
Why?
|
Health Services Accessibility | 1 | 2024 | 5440 | 0.070 |
Why?
|
Software | 1 | 2020 | 4434 | 0.070 |
Why?
|
Young Adult | 6 | 2024 | 59243 | 0.070 |
Why?
|
Breast Neoplasms | 2 | 2024 | 21012 | 0.060 |
Why?
|
Insulin-Like Growth Factor I | 1 | 2013 | 1934 | 0.060 |
Why?
|
Cyclophosphamide | 1 | 2011 | 2218 | 0.060 |
Why?
|
Fluorouracil | 1 | 2010 | 1641 | 0.060 |
Why?
|
Inflammatory Bowel Diseases | 1 | 2019 | 2422 | 0.060 |
Why?
|
1-Acylglycerophosphocholine O-Acyltransferase | 1 | 2024 | 9 | 0.060 |
Why?
|
Arthritis, Rheumatoid | 1 | 2020 | 3763 | 0.060 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2018 | 3080 | 0.060 |
Why?
|
Maytansine | 1 | 2024 | 86 | 0.060 |
Why?
|
Phytochrome A | 1 | 2023 | 2 | 0.060 |
Why?
|
Disease Progression | 4 | 2023 | 13506 | 0.060 |
Why?
|
Histone Deacetylase Inhibitors | 2 | 2023 | 774 | 0.060 |
Why?
|
Prognosis | 4 | 2020 | 29625 | 0.050 |
Why?
|
Pregnancy | 2 | 2024 | 29874 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3084 | 0.050 |
Why?
|
Adrenal Cortex Neoplasms | 1 | 2024 | 161 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3204 | 0.050 |
Why?
|
Chemokine CCL5 | 1 | 2022 | 214 | 0.050 |
Why?
|
Interleukin-5 | 1 | 2022 | 269 | 0.050 |
Why?
|
Philadelphia Chromosome | 1 | 2022 | 117 | 0.050 |
Why?
|
Proto-Oncogene Proteins c-sis | 1 | 2022 | 255 | 0.050 |
Why?
|
Quality of Life | 1 | 2023 | 13367 | 0.050 |
Why?
|
Early Termination of Clinical Trials | 1 | 2021 | 69 | 0.050 |
Why?
|
Vaccination | 2 | 2024 | 3384 | 0.050 |
Why?
|
Survival Rate | 3 | 2020 | 12725 | 0.050 |
Why?
|
Follow-Up Studies | 3 | 2020 | 39106 | 0.040 |
Why?
|
Azetidines | 1 | 2021 | 142 | 0.040 |
Why?
|
Gene Expression Regulation | 1 | 2018 | 11903 | 0.040 |
Why?
|
Tacrolimus | 1 | 2024 | 733 | 0.040 |
Why?
|
Volatile Organic Compounds | 1 | 2021 | 86 | 0.040 |
Why?
|
Maximum Tolerated Dose | 2 | 2014 | 883 | 0.040 |
Why?
|
Membrane Glycoproteins | 1 | 2010 | 3702 | 0.040 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 1 | 2022 | 641 | 0.040 |
Why?
|
Drug Therapy, Combination | 2 | 2020 | 6310 | 0.040 |
Why?
|
Survival Analysis | 2 | 2024 | 10090 | 0.040 |
Why?
|
Drug Repositioning | 1 | 2021 | 233 | 0.040 |
Why?
|
Organ Culture Techniques | 1 | 2021 | 794 | 0.040 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2020 | 882 | 0.040 |
Why?
|
Brain Neoplasms | 1 | 2019 | 9031 | 0.040 |
Why?
|
Creatinine | 1 | 2024 | 1899 | 0.040 |
Why?
|
Tumor Burden | 1 | 2024 | 1893 | 0.040 |
Why?
|
Africa South of the Sahara | 1 | 2020 | 744 | 0.040 |
Why?
|
Adolescent | 5 | 2024 | 88319 | 0.040 |
Why?
|
fms-Like Tyrosine Kinase 3 | 1 | 2020 | 495 | 0.030 |
Why?
|
Mammals | 1 | 2022 | 1132 | 0.030 |
Why?
|
Cisplatin | 2 | 2014 | 1651 | 0.030 |
Why?
|
Doxorubicin | 1 | 2023 | 2224 | 0.030 |
Why?
|
Cytokines | 2 | 2022 | 7396 | 0.030 |
Why?
|
CD4 Lymphocyte Count | 1 | 2022 | 2571 | 0.030 |
Why?
|
Dogs | 1 | 2021 | 3839 | 0.030 |
Why?
|
Drug Interactions | 1 | 2020 | 1416 | 0.030 |
Why?
|
Methotrexate | 1 | 2022 | 1719 | 0.030 |
Why?
|
Early Diagnosis | 1 | 2020 | 1186 | 0.030 |
Why?
|
Data Collection | 1 | 2024 | 3322 | 0.030 |
Why?
|
Databases, Factual | 2 | 2021 | 7967 | 0.030 |
Why?
|
Infusions, Intravenous | 1 | 2019 | 2219 | 0.030 |
Why?
|
Lymphocytes | 1 | 2022 | 2612 | 0.030 |
Why?
|
Immunotherapy, Adoptive | 1 | 2024 | 1469 | 0.030 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2023 | 3514 | 0.030 |
Why?
|
ADP Ribose Transferases | 1 | 2014 | 90 | 0.030 |
Why?
|
Risk Factors | 3 | 2017 | 74206 | 0.030 |
Why?
|
Exotoxins | 1 | 2014 | 121 | 0.030 |
Why?
|
Case-Control Studies | 1 | 2012 | 22176 | 0.030 |
Why?
|
Hypothyroidism | 1 | 2019 | 668 | 0.030 |
Why?
|
Mice | 4 | 2024 | 81525 | 0.030 |
Why?
|
Piperidines | 1 | 2021 | 1656 | 0.030 |
Why?
|
Evolution, Molecular | 1 | 2021 | 1886 | 0.030 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2023 | 9280 | 0.030 |
Why?
|
Immunologic Factors | 1 | 2022 | 1589 | 0.030 |
Why?
|
Blood Cell Count | 1 | 2013 | 397 | 0.030 |
Why?
|
Body Weight | 1 | 2023 | 4618 | 0.030 |
Why?
|
Lymphocyte Subsets | 1 | 2013 | 310 | 0.030 |
Why?
|
Immunoglobulin G | 1 | 2024 | 4544 | 0.030 |
Why?
|
DNA Repair | 1 | 2021 | 2045 | 0.030 |
Why?
|
Genome | 1 | 2020 | 1740 | 0.030 |
Why?
|
Host-Pathogen Interactions | 1 | 2020 | 1459 | 0.020 |
Why?
|
CA-125 Antigen | 1 | 2014 | 281 | 0.020 |
Why?
|
Sex Distribution | 1 | 2017 | 2281 | 0.020 |
Why?
|
Folic Acid Antagonists | 1 | 2011 | 75 | 0.020 |
Why?
|
Hypersensitivity | 1 | 2020 | 1171 | 0.020 |
Why?
|
Age Distribution | 1 | 2017 | 2880 | 0.020 |
Why?
|
Sequence Analysis, DNA | 1 | 2021 | 4740 | 0.020 |
Why?
|
Virulence Factors | 1 | 2014 | 513 | 0.020 |
Why?
|
Child | 3 | 2023 | 80153 | 0.020 |
Why?
|
Health Care Surveys | 1 | 2017 | 2426 | 0.020 |
Why?
|
Infant | 2 | 2023 | 36192 | 0.020 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2022 | 4369 | 0.020 |
Why?
|
Vinblastine | 1 | 2011 | 488 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2022 | 3060 | 0.020 |
Why?
|
Child, Preschool | 2 | 2023 | 42230 | 0.020 |
Why?
|
Lymphocyte Count | 1 | 2011 | 778 | 0.020 |
Why?
|
Bacterial Toxins | 1 | 2014 | 931 | 0.020 |
Why?
|
Risk | 1 | 2020 | 9610 | 0.020 |
Why?
|
Hydroxamic Acids | 1 | 2011 | 481 | 0.020 |
Why?
|
Cohort Studies | 2 | 2021 | 41487 | 0.020 |
Why?
|
Drug Therapy | 1 | 2011 | 503 | 0.020 |
Why?
|
Pneumonia | 1 | 2019 | 2143 | 0.020 |
Why?
|
Registries | 1 | 2023 | 8224 | 0.020 |
Why?
|
Cause of Death | 1 | 2017 | 3683 | 0.020 |
Why?
|
Myeloid Cells | 1 | 2011 | 823 | 0.020 |
Why?
|
Medicare | 1 | 2024 | 6770 | 0.020 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2023 | 9000 | 0.020 |
Why?
|
Phenotype | 1 | 2024 | 16591 | 0.020 |
Why?
|
Proteins | 1 | 2020 | 6032 | 0.020 |
Why?
|
Pain | 1 | 2020 | 5073 | 0.020 |
Why?
|
Gene Expression Profiling | 1 | 2021 | 9420 | 0.020 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2019 | 5305 | 0.010 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 3810 | 0.010 |
Why?
|
Membrane Proteins | 1 | 2020 | 7856 | 0.010 |
Why?
|
Socioeconomic Factors | 1 | 2017 | 7827 | 0.010 |
Why?
|
Smoking | 1 | 2020 | 9053 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2023 | 26198 | 0.010 |
Why?
|
Comorbidity | 1 | 2017 | 10508 | 0.010 |
Why?
|
Radiography | 1 | 2013 | 6965 | 0.010 |
Why?
|
Aging | 1 | 2021 | 8708 | 0.010 |
Why?
|
Mice, Inbred BALB C | 1 | 2011 | 6216 | 0.010 |
Why?
|
Risk Assessment | 1 | 2022 | 23995 | 0.010 |
Why?
|
Prevalence | 1 | 2017 | 15732 | 0.010 |
Why?
|
Time Factors | 1 | 2021 | 39967 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2010 | 10766 | 0.010 |
Why?
|
Bacterial Proteins | 1 | 2011 | 3847 | 0.010 |
Why?
|
T-Lymphocytes | 1 | 2011 | 10194 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2020 | 36426 | 0.010 |
Why?
|